Care hf trial nejm

The results of the EMPEROR-Preserved trial now published in NEJM have shown significant reduction in the combined risk of cardiovascular death or hospitalization with empagliflozin in patients with heart failure and a preserved ejection fraction HFpEF , regardless of the presence or absence of diabetes.

SGLT2 inhibitors empagliflozin and dapagliflozin have been shown to reduce the risk of hospitalization for heart failure and cardiovascular death in patients with chronic heart failure and a reduced ejection fraction.

However, prospective, clinical trials of SGLT inhibitors in patients with chronic heart failure and a preserved ejection fraction are need of the hour. Patients were randomly assigned to receive either empagliflozin at a dose of 10 mg per day or placebo and were followed for a median of The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. The trial had following major results:.

A benefit of empagliflozin was also seen with respect to the secondary outcome of the total number of hospitalizations for heart failure. The benefit of empagliflozin with respect to the primary outcome was independent of diabetes status. Although the effect on mortality is not very robust but Mark H. Drazner, M. Methods: Patients with New York Heart Association class III or IV heart failure due to left ventricular systolic dysfunction and cardiac dyssynchrony who were receiving standard pharmacologic therapy were randomly assigned to receive medical therapy alone or with cardiac resynchronization.

The primary end point was the time to death from any cause or an unplanned hospitalization for a major cardiovascular event. The principal secondary end point was death from any cause.

Results: A total of patients were enrolled and followed for a mean of Categories : Usable articles Cardiology Articles using time-sensitive statement from June Hidden category: Articles using time-sensitive statements. Navigation menu Personal tools Create account Log in.

Namespaces Page Discussion. Views Read View source View history. This page was last modified on 26 March , at